Instrument Inactif

Communiqués Pardes Biosciences, Inc.

Actions

PRDS

US69945Q1058

Recherche biotechnologique et médicale

Communiqués

31/08/23	Pardes Biosciences Announces Closing of Tender Offer	AQ
28/08/23	MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences	BU
17/08/23	MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares	BU
07/08/23	PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS	BU
21/07/23	PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS	BU
17/07/23	Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights	AQ
18/05/23	PARDES BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
05/05/23	PARDES BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
05/05/23	PARDES BIOSCIENCES, INC. : Results of Operations and Financial Condition (form 8-K)	AQ
05/05/23	Pardes Biosciences Reports First Quarter 2023 Financial Results	AQ
21/04/23	PARDES BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
03/04/23	PARDES BIOSCIENCES, INC. : Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
03/04/23	Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19	AQ
14/03/23	PARDES BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
14/03/23	PARDES BIOSCIENCES, INC. : Results of Operations and Financial Condition (form 8-K)	AQ
14/03/23	Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update	AQ
01/02/23	Pardes Biosciences to Present at SVB Securities Global Biopharma Conference	AQ
31/01/23	RM LAW Announces Investigation of Pardes Biosciences, Inc.	PR
07/11/22	PARDES BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
07/11/22	PARDES BIOSCIENCES, INC. : Results of Operations and Financial Condition (form 8-K)	AQ
07/11/22	Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update	AQ
01/11/22	Pardes Biosciences to Present at Jefferies London Healthcare Conference	AQ
20/10/22	Pardes Biosciences : Discovery and Development of PBI-0451	PU
18/10/22	Pardes Biosciences : Corporate Presentation October 2022	PU
17/10/22	PARDES BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)	AQ